ich habe diese nachricht schon lange versprochen, jetzt ist sie da!!!
Biokeys (BKYS) ist also eindeutig ein geheimtipp!
Biokeys Pharmaceuticals Inc. Announces Filing of Form 10-SB
with the United States Securities and Exchange Commission
SAN DIEGO--(BW HealthWire)--Oct. 9, 2001--Biokeys Pharmaceuticals Inc. (Pink Sheets:BKYS)
announced today the filing of Form 10-SB with the United States Securities and Exchange
Commission. The filing is accompanied by the Company's audited financial statements for the years
ended Dec. 31, 1999 and 2000, prepared by KPMG, L.P., the Company's auditor since 1996. After
the SEC review period and the filing being declared effective, the Company will become a fully
reporting company under the Securities Exchange Act of 1934. Biokeys Pharmaceuticals will then
immediately reapply for trading on the Over the Counter Bulletin Board (OTC-BB) and as soon as
possible thereafter, make application for listing on the American Stock Exchange.
Biokeys Pharmaceuticals Inc. is a biopharmaceutical research and development company whose
business strategy is to commercialize leading edge medical research through licensing agreements
with prominent universities and research institutions. The Company focuses its energy in cancer and
antiviral research to launch products that either extend the usefulness of current therapies or
replace marginal therapies with new approaches to treatment. The Company's lead compound,
CoFactor(TM), is a chemotherapy biomodulator designed to be used in conjunction with 5-FU, the
world's most frequently used cancer drug. CoFactor is being readied to enter Phase II/III human
clinical trials in the U.S. and Europe. Also in development is EradicAide(TM), a cell mediated,
antibody-negative immunotherapeutic/vaccine for HIV Infection/AIDS. In recently completed primate
trials, EradicAide has shown the ability to reduce HIV viral loads to undetectable levels with no
development of viral disease or resistance. For more information on these products and
technologies, please refer to the Company's newly updated Web site at www.biokeys.com.
This press release contains forward-looking statements within the meaning of the ``safe harbor''
provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based
on management's current expectations and beliefs. Actual results may vary from those currently
anticipated based upon a number of factors, including uncertainties inherent in the drug
development process, the timing and success of clinical trials, and the receipt of necessary
approvals from the United States Food and Drug Administration. The Company undertakes no
obligation to release publicly any revisions, which may be made to reflect events or circumstances
after the date hereof.
Contact:
Biokeys Pharmaceuticals Inc., Houston
Warren C. Lau, 281/272-0000
Biokeys (BKYS) ist also eindeutig ein geheimtipp!
Biokeys Pharmaceuticals Inc. Announces Filing of Form 10-SB
with the United States Securities and Exchange Commission
SAN DIEGO--(BW HealthWire)--Oct. 9, 2001--Biokeys Pharmaceuticals Inc. (Pink Sheets:BKYS)
announced today the filing of Form 10-SB with the United States Securities and Exchange
Commission. The filing is accompanied by the Company's audited financial statements for the years
ended Dec. 31, 1999 and 2000, prepared by KPMG, L.P., the Company's auditor since 1996. After
the SEC review period and the filing being declared effective, the Company will become a fully
reporting company under the Securities Exchange Act of 1934. Biokeys Pharmaceuticals will then
immediately reapply for trading on the Over the Counter Bulletin Board (OTC-BB) and as soon as
possible thereafter, make application for listing on the American Stock Exchange.
Biokeys Pharmaceuticals Inc. is a biopharmaceutical research and development company whose
business strategy is to commercialize leading edge medical research through licensing agreements
with prominent universities and research institutions. The Company focuses its energy in cancer and
antiviral research to launch products that either extend the usefulness of current therapies or
replace marginal therapies with new approaches to treatment. The Company's lead compound,
CoFactor(TM), is a chemotherapy biomodulator designed to be used in conjunction with 5-FU, the
world's most frequently used cancer drug. CoFactor is being readied to enter Phase II/III human
clinical trials in the U.S. and Europe. Also in development is EradicAide(TM), a cell mediated,
antibody-negative immunotherapeutic/vaccine for HIV Infection/AIDS. In recently completed primate
trials, EradicAide has shown the ability to reduce HIV viral loads to undetectable levels with no
development of viral disease or resistance. For more information on these products and
technologies, please refer to the Company's newly updated Web site at www.biokeys.com.
This press release contains forward-looking statements within the meaning of the ``safe harbor''
provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based
on management's current expectations and beliefs. Actual results may vary from those currently
anticipated based upon a number of factors, including uncertainties inherent in the drug
development process, the timing and success of clinical trials, and the receipt of necessary
approvals from the United States Food and Drug Administration. The Company undertakes no
obligation to release publicly any revisions, which may be made to reflect events or circumstances
after the date hereof.
Contact:
Biokeys Pharmaceuticals Inc., Houston
Warren C. Lau, 281/272-0000
